Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
Exscientia today announced that Sumitomo Pharma plans to initiate a Phase 1 clinical study of […]
Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline
Exscientia today announced the opening of a 21,000 square foot expansion of its facilities at […]
Exscientia Accelerates COVID-19 Drug Discovery Using AI
Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy […]
EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines
EQRx, a company committed to developing and delivering important new medicines to patients at radically […]
Exscientia Announces Second Molecule Created Using AI from Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial
Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., […]
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials
Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more